Shoreline Biosciences
Lyuda Hillman has held various finance and accounting roles throughout their career. Lyuda began as an Audit Senior at Ernst & Young in 2004 before moving on to roles such as Financial Reporting Manager at Cytori Therapeutics, Sr. Accounting Manager at Ambrx and Celladon Corporation, and Sr. Director Finance and Controller at Viking Therapeutics, Inc. Lyuda currently serves as Vice President & Controller at Shoreline Biosciences, Inc. Their experience spans from 2004 to the present day, showcasing their expertise and progression in the field.
From 2000 to 2003, Lyuda Hillman attended San Diego State University, where they obtained a Master's degree. The field of study for their degree is not specified.
Shoreline Biosciences
Shoreline's proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cells to improve anti-cancer activity.